With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.
Hiddo J. L. Heerspink, PhD
Advertisement
Hiddo J.L. Heerspink, PhD, is principal investigator of the FINE-ONE trial and professor of clinical trials at the University Medical Center Groningen.
Articles by Hiddo J. L. Heerspink, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5